Meeder Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Meeder Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-760	Closed	-$46K	–	1786
2018 Q4	$46K	Buy	760 +643	+550%	+$63.5K	﹤0.01%	833
2018 Q3	$17K	Buy	117 +96	+457%	+$11.7K	﹤0.01%	1063
2018 Q2	$2.61K	Buy	21 +8	+62%	+$680	﹤0.01%	1383
2018 Q1	$1K	Sell	13 -111	-90%	-$9.41K	﹤0.01%	1459
2017 Q4	$7K	Sell	124 -8	-6%	-$361	﹤0.01%	1225
2017 Q3	$6K	Buy	132 +5	+4%	+$208	﹤0.01%	1210
2017 Q2	$5K	Buy	127 +56	+79%	+$2.86K	﹤0.01%	1192
2017 Q1	$4K	Sell	71 -447	-86%	-$22.2K	﹤0.01%	1166
2016 Q4	$20K	Buy	518 +386	+292%	+$15.7K	﹤0.01%	653
2016 Q3	$5K	Buy	+132	New	+$6K	﹤0.01%	720

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Meeder Asset Management's LRMR Position: Q1 2019 in Review

Meeder Asset Management sold out of Larimar Therapeutics (LRMR) in Q1 2019, closing a stake of 760 shares — an estimated $46K sold.

Meeder Asset Management first reported a position in LRMR in Q3 2016 and held it in 10 quarters. The position peaked at $46K in Q4 2018. 85 funds tracked by Wall St. Rank hold LRMR as of Q1 2019.

Meeder Asset Management reported no remaining Larimar Therapeutics position as of Q1 2019 after selling out during the quarter.
Meeder Asset Management sold 760 Larimar Therapeutics shares in Q1 2019, an estimated $46K.
Meeder Asset Management first reported a position in Larimar Therapeutics in Q3 2016 and held it in 10 quarters.
Meeder Asset Management's Larimar Therapeutics position peaked at $46K in Q4 2018.
85 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2019.

Based on Meeder Asset Management's 13F filing for Q1 2019, filed 16 Apr 2019.